A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
An Almost Normal Life Expectancy for People With HIV?
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Misleading News Reports Suggest HIV Cure Is Near
New HIV Drug Class Shows Promise
Gene Therapy Shows Promise in Controlling HIV
Potential Microbicide Tricks HIV Into Sudden Death
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

September 14, 2011

Unlocking Blood-Brain Barrier May Improve Neurological Treatment Outcomes

Researchers at Cornell’s College of Veterinary Medicine may have solved a problem that has long vexed neurologists, including those involved in treating and studying HIV/AIDS-related neurological problems. According to a new report published in the September 14 issue of The Journal of Neuroscience, the Cornell team has found a way to open and close the blood-brain barrier, which may allow for more effective treatment of a variety of brain-centered diseases and complications, such as those associated with HIV/AIDS.

The researchers found that adenosine, a molecule produced by the body, can modulate the entry of large molecules—such as those that make up drugs needed to treat neurological disorders, infectious diseases and cancers—into the brain. They discovered that when adenosine receptors are activated on cells that comprise the blood-brain barrier, a gateway through the blood-brain barrier can be established.

Although the study was done on mice, the Cornell team, under the direction of Margaret Bynoe, PhD, also found that adenosine receptors affect the same cells in humans. What’s more, they confirmed that an existing FDA-approved drug called Lexiscan (regadenoson), an adenosine-based drug used in heart imaging in very ill patients, can briefly open the gateway across the blood-brain barrier.

The biggest hurdle for every neurological disease—including those related to HIV infection, such as HIV-associated neurocognitive disorder (HAND), AIDS-related dementia and a host of AIDS-related opportunistic infections—is the inability to easily deliver drugs into the brain. This is largely because of the blood-brain barrier, which consists of specialized cells that make up the brain’s blood vessels. It selectively prevents substances from entering the blood and brain, only allowing such essential molecules as amino acids, oxygen, glucose and water to pass through.

Researchers have tried to deliver drugs to the brain by modifying them so they would bind to receptors and “piggyback” onto other molecules to get across the barrier. But so far, this modification process has decreased the drugs’ efficacy.

According to the paper authored by Bynoe and her colleagues, the researchers were able to transport large molecules, such as antibodies, into the mice brains. No drugs used to treat any neurological diseases, including antiretrovirals or medications used to manage brain-related opportunistic infections, were studied. 

The researchers did, however, successfully deliver anti-beta amyloid antibodies across the blood-brain barrier. These antibodies bind to beta-amyloid plaques, which are known to cause Alzheimer’s disease, at least in the mouse model.

Although there are many known antagonists—drugs or proteins that specifically block signaling—for adenosine receptors in mice, Bynoe and her colleagues note that future work will be needed to identify such drugs for humans.

Search: blood-brain barrier, BBB, brain, central nervous system, adenosine, Lexiscan, regadenoson, mice


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    dave41
    Bethany
    Oklahoma


    Sloan1
    Dallas
    Texas


    youngbloodlatino
    Columbia
    Maryland


    robert12
    Queens
    New York
Click here to join POZ Personals!
Conference Coverage

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


20th Conference on Retroviruses and Opportunistic Infections
(CROI 2013)
Atlanta, GA
March 3 - 7, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.